COVID-19 in Immunocompromised Hosts: What We Know So Far - PubMed (original) (raw)

Review

COVID-19 in Immunocompromised Hosts: What We Know So Far

Monica Fung et al. Clin Infect Dis. 2021.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk of more severe disease but who may also have decreased detrimental inflammatory responses, are not well characterized. We review the existing literature on COVID-19 among immunocompromised populations ranging from patients with cancer and solid-organ transplant recipients to patients with HIV and those receiving immunomodulatory therapy for autoimmune disease. Patients with malignancy and solid-organ transplant recipients may be at increased risk of severe COVID-19 disease and death, whereas for those with other types of immunocompromise, current evidence is less clear. Overall, further prospective controlled studies are needed to determine the attributable risk of immunocompromising conditions and therapies on COVID-19 disease prognosis.

Keywords: COVID-19; biologics; cancer; immunocompromised; transplant.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

PubMed Disclaimer

Comment in

References

    1. World Health Organization. WHO statement regarding cluster of pneumonia cases in Wuhan, China Published 2019. Available at: https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding.... Accessed 4 August 2020.
    1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. Published online February 2020; 20:533–4. doi: 10.1016/S1473-3099(20)30120-1. -DOI -PMC -PubMed
    1. Manuel O, Estabrook M; American Society of Transplantation Infectious Diseases Community of Practice RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13511. -PMC -PubMed
    1. Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood 2016; 127:2682–92. -PMC -PubMed
    1. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033–34. -PMC -PubMed

Publication types

MeSH terms

LinkOut - more resources